{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:43:00Z","timestamp":1747172580547,"version":"3.40.5"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T00:00:00Z","timestamp":1412208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Upsher-Smith Laboratories, Inc."}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.yebeh.2014.09.061","type":"journal-article","created":{"date-parts":[[2014,10,21]],"date-time":"2014-10-21T20:00:12Z","timestamp":1413921612000},"page":"136-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Efficacy of once-daily extended-release topiramate (USL255): A subgroup analysis based on the level of treatment resistance"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1151-7083","authenticated-orcid":false,"given":"R. Edward","family":"Hogan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balduin","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatesh","family":"Nagaraddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toufic A.","family":"Fakhoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bob","family":"Anders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie M.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Laine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark B.","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve S.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2014.09.061_bb0005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14728214.12.3.407","article-title":"Emerging drugs for epilepsy","volume":"12","author":"Kwan","year":"2007","journal-title":"Expert Opin Emerg Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.yebeh.2014.09.061_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/epi.12175","article-title":"Road to refractory epilepsy: the Glasgow story","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","article-title":"Quantifying the response to antiepileptic drugs: effect of past treatment history","volume":"70","author":"Schiller","year":"2008","journal-title":"Neurology"},{"year":"2014","series-title":"Topamax prescribing information","author":"Janssen Pharmaceuticals Inc.","key":"10.1016\/j.yebeh.2014.09.061_bb0020"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0025","first-page":"62","article-title":"USL255, extended-release topiramate, demonstrates dose-proportional pharmacokinetics and tolerability over a wide dosing range in healthy subjects","volume":"54","author":"Halvorsen","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0030","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/j.1528-1167.2011.03183.x","article-title":"Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate","volume":"52","author":"Lambrecht","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0035","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/epi.12225","article-title":"Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation","volume":"54","author":"Bialer","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0040","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/epi.12660","article-title":"Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study","volume":"55","author":"Chung","year":"2014","journal-title":"Epilepsia"},{"year":"2014","series-title":"Qudexy XR NDA approval","author":"Food and Drug Administration (FDA)","key":"10.1016\/j.yebeh.2014.09.061_bb0045"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0050","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3111\/13696998.2012.751918","article-title":"Antiepileptic drug treatment patterns and economic burden of commercially-insured patients with refractory epilepsy with partial onset seizures in the United States","volume":"16","author":"Chen","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0733-8619(18)30107-5","article-title":"Quality of life for people with epilepsy","volume":"12","author":"Cramer","year":"1994","journal-title":"Neurol Clin"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0060","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11910-007-0051-1","article-title":"Seizure-related injury and death","volume":"7","author":"Nei","year":"2007","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0065","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1046\/j.1528-1157.2002.40001.x","article-title":"Risk factors for suicide in epilepsy: a case control study","volume":"43","author":"Nilsson","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1600-0404.2005.00506.x","article-title":"Adverse effects of antiepileptic drugs","volume":"181","author":"Perucca","year":"2005","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0075","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0080","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2014.09.061_bb0085","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ana.21064","article-title":"Results of treatment changes in patients with apparently drug-resistant chronic epilepsy","volume":"62","author":"Luciano","year":"2007","journal-title":"Ann Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505014004971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505014004971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T08:46:24Z","timestamp":1565945184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505014004971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":17,"alternative-id":["S1525505014004971"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2014.09.061","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of once-daily extended-release topiramate (USL255): A subgroup analysis based on the level of treatment resistance","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2014.09.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}